Biliary Atresia

Biliary atresia is a rare but serious condition in which the bile ducts — the small tubes that carry bile from the liver to the small intestine — are absent, blocked, or severely scarred. As a result, bile cannot flow out of the liver as it should.

To understand why this matters, it helps to understand what bile does. The liver produces bile continuously — it is essential for digesting fats and absorbing fat-soluble vitamins. Normally, bile flows from the liver through the bile ducts into the small intestine, where it does its digestive work before being partially reabsorbed and recycled. In biliary atresia, that pathway is obstructed or missing entirely.

When bile cannot drain, it backs up inside the liver. This causes progressive inflammation and scarring — a process that, if untreated, leads to cirrhosis within the first years of life. The liver, unable to drain normally, deteriorates at a rate that is rapid by adult liver disease standards. Without intervention, most children with untreated biliary atresia develop end-stage liver disease within two years of birth.

Biliary atresia affects approximately one in every 10,000 to 15,000 live births. It occurs slightly more commonly in girls than boys and is more prevalent in Asian populations. It is not hereditary in the conventional sense — it does not run predictably in families — and it is not caused by anything the parents did or did not do during pregnancy.

This is a question that has occupied researchers for decades, and the honest answer is that the exact cause of biliary atresia is not fully understood. What is clear is that it is not a single-cause disease — it is likely the result of multiple interacting factors.

Abnormal bile duct development during foetal life is one proposed mechanism. In fetal biliary atresia — a less common form that accounts for roughly 10 to 15 percent of cases — the bile ducts fail to develop properly during gestation. This form is often associated with other structural abnormalities, including situs inversus (reversal of organ positions), polysplenia (multiple small spleens), or heart defects. The presence of these associated anomalies suggests a disruption in early organ development.

Viral infection is one of the most studied potential triggers for the more common perinatal or postnatal form. Several viruses — including reovirus, rotavirus, cytomegalovirus (CMV), and Epstein-Barr virus — have been detected in bile duct tissue of affected infants, and animal models have shown that certain viral infections can trigger bile duct inflammation and obstruction in genetically susceptible individuals. However, no single virus has been definitively proven to cause biliary atresia in humans.

Autoimmune or inflammatory mechanisms are strongly implicated. Many researchers believe that in susceptible individuals, an initial trigger — viral or otherwise — initiates an abnormal immune response that specifically targets the bile duct epithelium, causing progressive inflammation, obliteration, and fibrosis of the duct system. This theory is supported by the presence of activated immune cells and inflammatory markers in bile duct tissue from affected babies.

Genetic susceptibility likely plays a role — not as a direct inherited cause, but as a predisposition that makes certain individuals more vulnerable to whatever environmental trigger initiates the disease process.

Biliary atresia presents in the newborn period, and its symptoms while distinctive once you know what to look for are easy to miss in the early weeks of life when some degree of neonatal jaundice is common and expected.

Prolonged jaundice is the hallmark symptom. All newborns develop some degree of jaundice in the first days of life as their liver adapts to processing bilirubin outside the womb — this physiological jaundice is normal and resolves within two weeks. In biliary atresia, jaundice does not resolve. It persists and often deepens beyond two weeks of age. The skin and the whites of the eyes remain yellow, and the colour may intensify over weeks.

Pale or clay-coloured stools are one of the most important warning signs. Normal infant stools are yellow, mustardy, or green the colour comes from bile pigments. When bile cannot reach the intestine, stools lose their colour and become pale, white, grey, or clay-like. This is a red flag that should prompt immediate medical evaluation. Many countries now include a stool colour card in newborn health materials specifically to help parents identify this sign.

Dark urine — tea or amber coloured develops as the body excretes bilirubin through the kidneys instead of the bile ducts. Noticing unusually dark urine in a jaundiced infant warrants urgent attention.

Abdominal swelling may become noticeable as the liver and spleen enlarge in response to bile obstruction and developing portal hypertension. The abdomen may feel firm or look distended.

Poor weight gain and feeding difficulties can develop as fat malabsorption caused by insufficient bile in the intestine leads to nutritional deficiencies. Affected infants may feed poorly, gain weight slowly, and appear generally unwell compared to healthy newborns.

Irritability and generalised discomfort, while non-specific, are commonly reported by parents of affected infants.

The critical window for biliary atresia treatment in baby is the first 60 days of life ideally within the first 45 days. The sooner the diagnosis is established and surgery performed, the better the outcome. This makes parental awareness of these symptoms genuinely life-changing.

Diagnosing biliary atresia requires a combination of clinical assessment, blood tests, imaging, and ultimately surgical exploration — because no single non-invasive test can confirm the diagnosis with absolute certainty in all cases.

Blood tests are the starting point. Liver function tests show elevated bilirubin — with a characteristic pattern of predominantly conjugated (direct) hyperbilirubinemia, which distinguishes biliary obstruction from other causes of neonatal jaundice. Elevated liver enzymes (GGT, ALT, AST) and alkaline phosphatase support the suspicion of bile duct disease.

Ultrasound of the liver and bile ducts is performed early in the evaluation. While ultrasound cannot directly visualise the obstructed bile ducts in biliary atresia, it provides important clues — the gallbladder may be small, absent, or poorly contractile. The triangular cord sign — a triangular echogenic density at the liver hilum — is a specific ultrasound finding that, when present, strongly suggests biliary atresia. Ultrasound also assesses liver size, spleen size, and portal vein blood flow.

Hepatobiliary iminodiacetic acid (HIDA) scan — also called a hepatobiliary scintigraphy or cholescintigraphy — uses a radiotracer that is taken up by liver cells and excreted into bile. In biliary atresia, the tracer is absorbed by the liver normally but not excreted into the intestine — confirming biliary obstruction. This test is highly sensitive but not perfectly specific.

Liver biopsy provides histological information about the degree of fibrosis and bile duct changes. Biopsy findings of bile duct proliferation, bile plugs, and portal fibrosis are characteristic of biliary atresia and help distinguish it from other causes of neonatal cholestasis.

Intraoperative cholangiogram is the definitive diagnostic step. During surgery, contrast dye is injected directly into the biliary system and X-rays are taken to visualise the bile ducts. In biliary atresia, the expected duct anatomy is absent or obliterated. This finding confirms the diagnosis and immediately triggers the surgical repair.

Treatment for biliary atresia is surgical there is no medication that can open blocked bile ducts or reverse the obliterative process. The goal of treatment is to restore bile flow from the liver to the intestine as quickly as possible, before irreversible liver damage accumulates.

The Kasai Procedure (Hepatoportoenterostomy)

The Kasai procedure named after the Japanese surgeon Morio Kasai who developed it in the 1950s is the primary surgical treatment for biliary atresia and the first intervention performed in virtually all affected infants.

The procedure works by removing the obstructed, scarred bile ducts and attaching a loop of the infant's own small intestine directly to the liver hilum the area of the liver where the bile ducts exit. This creates a new pathway for bile to drain from the liver directly into the intestine, bypassing the absent or obliterated duct system entirely.

The operation typically takes three to four hours and is performed under general anaesthesia. It requires a highly experienced paediatric surgical team with specific expertise in hepatobiliary surgery — outcomes are consistently better at high-volume specialist centres.

How well does the Kasai procedure work?

Success depends critically on age at surgery. Infants operated on before 45 days of age have the best outcomes approximately 80 percent achieve adequate bile drainage (defined as a bilirubin level below 20 μmol/L at three months post-operatively). Infants operated between 45 and 60 days have intermediate outcomes. Beyond 90 days, the procedure has significantly lower success rates, though it is still generally performed as it may extend the time before transplantation is needed and improve the child's nutritional status and growth.

Even when the Kasai procedure achieves good initial bile drainage, it does not cure biliary atresia. The underlying inflammatory process within the liver often continues, and many children who initially do well after Kasai gradually develop progressive fibrosis and eventually require liver transplantation. However, a successful Kasai can give a child years — sometimes a decade or more — of life before transplantation becomes necessary, which is enormously significant because older, larger children tolerate transplant surgery better and have access to a wider range of donor options.

Post-Kasai Medical Management

Surgery alone is not sufficient comprehensive medical management after the Kasai procedure is an essential component of pediatric biliary atresia treatment.

Prophylactic antibiotics are prescribed after surgery to reduce the risk of ascending cholangitis — bacterial infection travelling up the new biliary-intestinal connection into the liver, which is a common and serious complication.

Ursodeoxycholic acid a bile acid that promotes bile flow and has cytoprotective effects on liver cells is routinely prescribed post-operatively and continued long-term.

Fat-soluble vitamin supplementation (vitamins A, D, E, and K) is essential because impaired bile flow reduces fat absorption and depletes these critical nutrients. Vitamin K deficiency in particular raises bleeding risk significantly.

Nutritional support is a central priority. Infants with biliary atresia often have high caloric needs due to malabsorption and the metabolic demands of liver disease. Specialist dietitian input, high-calorie formula feeds, and in some cases nasogastric feeding are used to support adequate growth and development.

Treating Cholangitis

Ascending cholangitis fever, worsening jaundice, and deteriorating liver function following Kasai surgery is a serious complication requiring prompt hospitalisation and intravenous antibiotics. Repeated episodes of cholangitis damage the liver further and accelerate the need for transplantation.

Even with optimal pediatric biliary atresia treatment, biliary atresia carries a significant burden of complications that require ongoing monitoring and management.

• Progressive liver fibrosis and cirrhosis is the most fundamental complication — the underlying inflammatory process in the bile ducts drives ongoing scarring even when bile flow is partially restored. The rate of progression varies between individuals, but most children with biliary atresia develop some degree of cirrhosis by early childhood.
• Portal hypertension — elevated blood pressure in the portal vein caused by resistance from the scarred liver — leads to spleen enlargement, low platelet counts (increasing bleeding risk), and the development of varices. Oesophageal varices that rupture cause potentially life-threatening gastrointestinal bleeding and are a major complication requiring endoscopic surveillance and management.
• Ascending cholangitis is an infection of the biliary-intestinal anastomosis and liver that occurs in up to 50 to 60 percent of children after Kasai surgery. Each episode causes further liver damage and worsens the long-term prognosis.
• Nutritional deficiencies — particularly of fat-soluble vitamins — persist despite supplementation in many children and require regular monitoring with blood tests and ongoing dietitian input.
• Growth and developmental delay can result from chronic malnutrition, liver disease, and the physical burden of multiple hospitalisations and medical interventions. Multidisciplinary support including physiotherapy, occupational therapy, and developmental paediatrics plays an important role.
• Fat malabsorption causes steatorrhoea (fatty, foul-smelling stools) and impairs weight gain and height velocity.
• Hepatopulmonary syndrome — a complication where abnormal blood vessel connections in the lungs cause low oxygen levels — can develop in advanced liver disease and may accelerate the urgency for transplantation.

Liver transplantation is the definitive, life-saving treatment for children with biliary atresia whose liver disease progresses despite Kasai surgery — and it is the most common indication for paediatric liver transplantation worldwide.

Transplantation is considered when the Kasai procedure fails to achieve adequate bile drainage, when progressive liver failure develops despite initial surgical success, or when complications of portal hypertension become unmanageable. Specific indicators include persistent or worsening jaundice after Kasai surgery, recurrent uncontrolled cholangitis, variceal bleeding, refractory ascites, hepatopulmonary syndrome, severe growth failure, and declining synthetic liver function evidenced by falling albumin, rising INR, or rising bilirubin.

Biliary atresia treatment in baby through liver transplantation carries specific challenges in very young, small infants. The minimum weight threshold for transplantation at most centres is approximately 6 to 8 kg one reason why a successful Kasai procedure, even if temporary, is valuable: it allows the child to grow to a safer transplant weight.

Living donor liver transplantation where a parent or close relative donates a portion of their liver is particularly important in paediatric biliary atresia because it allows the transplant to be scheduled electively when the child is in the best possible condition, rather than waiting for a deceased donor organ. The donor's liver segment regenerates to near-normal size within weeks, and the child's transplanted segment grows with them.

Outcomes after liver transplantation for biliary atresia are among the best of any transplant indication. One-year survival exceeds 90 percent at experienced centres, and five-year survival is approximately 85 to 90 percent. Many children transplanted in infancy grow up to live completely normal lives attending school, participating in sport, and eventually living independently as adults.

Honest answer: biliary atresia cannot currently be prevented. Because its exact cause remains incompletely understood, there is no vaccine, screening test during pregnancy, or intervention that can reliably prevent its occurrence.

What can be prevented and what makes an enormous practical difference is late diagnosis. The damage caused by delayed treatment for biliary atresia is preventable. Every week between symptom onset and surgery in a young infant represents accumulated liver scarring that cannot be reversed.

Newborn stool colour screening programmes have been implemented in several countries most notably Taiwan where parents are provided with a stool colour card at birth and asked to compare their baby's stool colour with the card at each feed. Any pale or abnormal stool colour prompts immediate medical assessment. Taiwan's programme has measurably reduced the age at Kasai surgery and improved outcomes at a population level. Several other countries are evaluating similar programmes.

Parental awareness is therefore the most impactful preventive measure currently available. Knowing the warning signs prolonged jaundice beyond two weeks, pale stools, dark urine  and acting on them immediately rather than waiting to "see if it improves" is what allows surgeons to operate within the critical early window.

Prompt referral by general practitioners and paediatricians to specialist paediatric hepatology centres when biliary atresia is suspected is equally important. Delays in referral even of one to two weeks can shift a child from the high-success early surgical window to a later, less favourable timeframe.

Biliary atresia is a serious, life-altering condition but it is not one without hope, and it is not one without effective treatment. The Kasai procedure, when performed early and at an experienced centre, can restore bile flow and give a child years of growth and development before transplantation may become necessary. And when transplantation is needed, it offers the prospect of a full, normal life.

Biliary atresia treatment in baby has improved enormously over the past three decades driven by surgical refinements, better post-operative medical management, advances in transplant immunosuppression, and growing expertise at specialist paediatric centres. Children who would not have survived infancy a generation ago are today living as healthy young adults.

The most important message for any parent or caregiver reading this is: time matters above all else. If your newborn has persistent jaundice beyond two weeks, pale stools, or dark urine do not wait. See a doctor immediately and ask specifically about biliary atresia. The window for optimal surgical intervention is narrow, and acting within it is the single most powerful thing that can be done to protect your child's future. With the right care, the right team, and the right timing, the outlook for children with biliary atresia is far brighter than the diagnosis initially suggests.